Supporting the move from pediatric to adult rheumatology care for young people with childhood inflammatory rheumatic diseases.

Compassionate Care and Organization of Healthcare Services for a Successful Transition in Rheumatology

Observational Assistance Publique - Hôpitaux de Paris · NCT07469787

This project will see if a structured transition program (early preparation, a therapeutic education workshop, and a joint pediatric–adult visit) helps young people with childhood inflammatory rheumatic diseases manage their care after moving to adult rheumatology.

Quick facts

Study typeObservational
Enrollment50 (estimated)
Ages18 Years and up
SexAll
SponsorAssistance Publique - Hôpitaux de Paris Academic / other
Locations1 site (Le Kremlin-Bicêtre)
Trial IDNCT07469787 on ClinicalTrials.gov

What this trial studies

BOOST-R is a monocentric, non-interventional observational study at Bicêtre University Hospital examining real-world transition outcomes after transfer from pediatric to adult rheumatology. Adult patients who were followed in pediatric rheumatology and attended a joint pediatric–adult transition consultation between 2018 and 2024 are contacted by postal mail and invited to complete an online questionnaire. The study compares different transition modalities (education workshop plus joint consultation versus joint consultation only) using a validated French transition-readiness questionnaire and measures of self-management and follow-up. The design aims to capture real-life effectiveness of the implemented transition program rather than test a new intervention.

Who should consider this trial

Good fit: Adults (18+) with a diagnosed chronic inflammatory rheumatic disease who were previously followed in pediatric rheumatology at Bicêtre and who attended a joint pediatric–adult transition consultation between 2018 and 2024 are the intended participants.

Not a fit: Patients who were lost to follow-up, who did not participate in a joint pediatric–adult transition consultation, or who are under guardianship/curatorship/legal protection are excluded and unlikely to benefit from the study findings.

Why it matters

Potential benefit: If successful, the work could identify which transition approaches help young adults maintain treatment, keep follow-up appointments, and improve self-management after moving to adult care.

How similar studies have performed: Structured transition programs have shown benefits for autonomy and continuity in other chronic diseases and some pilot rheumatology efforts are promising, but robust real-world data in rheumatology remain limited.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age 18 years or older
* Diagnosis of chronic inflammatory rheumatic disease
* Previously followed in pediatric rheumatology at Bicêtre Hospital
* Participation in a joint pediatric-adult transition consultation between 2018 and 2024
* Affiliated with a health insurance system
* No objection expressed to participation after being informed about the study

Exclusion Criteria:

* Patient lost to follow-up
* No participation in a joint pediatric-adult transition consultation
* Patient under guardianship, curatorship, or legal protection

Where this trial is running

Le Kremlin-Bicêtre

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Chronic Inflammatory Rheumatic Diseases of ChildhoodJuvenile-Onset Chronic Inflammatory Rheumatic DiseasesTransition of Care in Chronic Inflammatory Rheumatic DiseasesContinuity of careTherapeutic patient educationSelf-managementTransitional carePediatric to adult transition
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.